Medarex - News - 500 Beiträge pro Seite

[Grosser Nargus]

Medarex makes breakthrough
By Adrian Michaels in New York
Published: August 6 2000 21:52GMT | Last Updated: August 7 2000 00:14GMT


A US biotechnology company will on Monday mark a breakthrough in research productivity by announcing it has successfully slashed the time it took to bring a drug from initial research to clinical trial.

Medarex will say that a drug it has developed for prostate cancer has gone into the first phase of clinical trials after just a year of research. Traditionally, drug development can take up to five years.

The company is using human antibody technology that is also being developed by pharmaceutical companies Novartis and Johnson & Johnson, as well as the biotech groups Immunex and Amgen.

The company says it hopes to use the technology to develop about 12 drugs a year.

Some senior industry executives admit that with US regulators approving only about 40 new drugs a year, some pharmaceutical companies will not be able to sustain the earnings growth rates they are promising investors.

Attention has focused, for example, on Pfizer, the sector`s largest company, which has forecast earnings growth at well over 20 per cent for the next two or three years while it saves costs from its merger with Warner-Lambert.

Some analysts say that to sustain that level, the company will have to discover or acquire at least seven or eight promising new drugs a year, a very high proportion of the total number of new drugs.

Companies such as Medarex believe, however, that the industry`s research productivity can be improved without jeopardising safety.

If so, it could bring faster gains from the recent completion of the human genetic code, allowing scientists more quickly to identify those parts of the code which are realistic targets for medical research.

Quelle: finacial times

[Mörzi]

Kann das jemand übersetzten?
Danke

[FrankieTheFly]

der kurs muss hoch heute kauf dir noch ein paar

[tic]

Auszugsweise Übersetzung der Michaels-Meldung zu Medarex:

Medarex schafft den Durchbruch
von Adrian Michaels in New York
...

Ein US-Biotech-Unternehmen wird am Montag den Durchbruch in der Forschungsproduktivität melden, indem es die Zeit von der Med-Forschung bis zur klinischen Testreihe auf ein Jahr verkürzt hat.
Medarex wird melden, daß das Unternehmen ein Arzneimittel gegen Prostatakrebs in die erste Phase der klinischen Tests nach lediglich einem Jahr medizinischer Entwicklung, wo die Arzneimittelentwicklung normalerweise bis zu 5 Jahre dauern kann.

Das Unternehmen verwendet eine Antikörper-Technologie, die auch von Pharmaunternehmen wie Novartis, Johnson & Johnson, Immunex und Amgen entwickelt wurde.

Das Unternehmen äußerte die Hoffnung, die Technologie zur Entwicklung von mind. 12 Arzneimitteln im Jahr einzusetzen.
...

[Kipferl]

sind das nicht eigentlich gigantische news die die gesante
medikamentenentwicklung revolutionieren oder irre ich mich da

das müsste dem kurs doch einen mächtigen anstieg geben

wie seht ihr das

K.

[Blackjack2000]

Medarex wird ihren Weg mit Sicherheit gehen!!!

MfG

[MSolver]

und noch etwas gutes :


Medarex Expands Business Development Capabilities; Appoints Ronald Pepin and James Cornett to Key Roles

WEDNESDAY, AUGUST 9, 2000 6:05:00 AM EST
PRINCETON, N.J., Aug 9, 2000 /PRNewswire via COMTEX/ -- Medarex, Inc. MEDX announced today that James B. Cornett, Ph.D. and Ronald A. Pepin, Ph.D. have joined the Company as Vice Presidents, Business Development, GenPharm International, Inc. (a wholly owned subsidiary of Medarex). Drs. Pepin and Cornett will focus their efforts on all aspects of business development, including forming alliances based on Medarex`s wide array of human antibody-based technologies and maintaining relationships with the Company`s 22 current partners.

Dr. Cornett was most recently Director, Business Development, at Protein Design Labs, Inc. (PDLI). In this capacity he initiated, developed and managed numerous partnering relationships involving the development of monoclonal antibodies. Prior to his position with PDLI, he held positions with Centocor, Inc. and Sterling-Winthrop Research Institute. Dr. Cornett earned a Ph.D. in molecular biology from the University of Arizona Medical School. Dr. Cornett will be based in the Company`s San Jose, California, facility.

Dr. Pepin served previously as Executive Director, External Science and Technology, at Bristol-Myers Squibb Company (BMS). In this position, he was responsible for the discovery, evaluation and negotiation of major alliances with pharmaceutical and biotechnology companies, and he successfully led several strategic initiatives in the field of genomics. During the past 10 years, he has held various positions with BMS in the fields of licensing and business development. Dr. Pepin earned a Ph.D. in biology from Georgetown University. Dr. Pepin will be based in the Company`s Princeton, New Jersey, office.

"There has been a growing demand from the pharmaceutical and biotechnology industries for Medarex`s antibody-based technologies. In order to satisfy this demand we are very pleased to have attracted such highly-skilled business development professionals. Ron Pepin and Jim Cornett are two of the most experienced business development professionals in the biopharmaceutical industry," said Donald L. Drakeman, President and CEO of Medarex. "Their expertise and in-depth knowledge of our industry will be a valuable asset to Medarex as we continue to expand our human antibody technology platform and our product development activities."

Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse(R) and TC Mouse(TM) systems for the creation of high-affinity, fully human antibodies; T-12 Development(SM) offering the capability of moving from target to trial in approximately 12 months; and Trans-Phage Technology(SM) combining high throughput screening with fully human antibody development. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about Medarex visit its web site at www.medarex.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of the company`s product candidates, uncertainties related to business opportunities, the receipt of future payments, the continuation of business partnerships and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

SOURCE Medarex, Inc

[ballard1]

ich will meine Medarex zurück, waren so schön volatil die ganze Zeit.
Wer kann mir noch Hoffnung machen, will um die $50-60 wieder rein.
Meinungen?

[ballard1]

ich will meine Medarex zurück, waren so schön volatil die ganze Zeit.
Wer kann mir noch Hoffnung machen, will um die $50-60 wieder rein.
Meinungen?

[ballard1]

ich will meine Medarex zurück, waren so schön volatil die ganze Zeit.
Wer kann mir noch Hoffnung machen, will um die $50-60 wieder rein.
Meinungen?

[janolo]

moin moin ballard one,

Du kannst ruhig meine MEDAREX haben zum Schnäppchenpreis von 120 Euro.
Hast zwar dann nur die Hälfte, aber du hast sie wieder.

Ist das nicht ein Angebot.

ich höre wieder

Ciao janolo

[janolo]

moin moin ballard one,

Du kannst ruhig meine MEDAREX haben zum Schnäppchenpreis von 120 Euro.
Hast zwar dann nur die Hälfte, aber du hast sie wieder.

Ist das nicht ein Angebot.

ich höre wieder

Ciao janolo

[ballard1]

@janolo zum Thema " Postings die, die Welt nicht braucht"

[janolo]

hey ballard the first,

...oh wie konnte ich nur; konnt`ja nicht wissen, daß Du keinen Spaß verstehst.

So was wird nie wieder vorkommen, o.k:?

Gruß vom erniedrigten
janolo

[DerAktionaer]

@ ballard1: Laß Dich nicht von Janolo abzocken. Hier die wirklich gute Nachricht des Tages: Verkaufe Dir meine 70 Medarex
für sage und schreibe 110€. Are you ready for transaction?

[janolo]

....bääääh, bin kein Abzocker Du Aktionär du.

Rädi vor Transäktschn
janolo

[ballard1]

@janolo, klar versteh ich Spaß, je schwärzer je besser.
ist schon wieder ok, happy trading

[MSolver]

ich denke das sieht nicht gut aus:

Thursday August 10, 6:01 am Eastern Time
Press Release
SOURCE: Medarex, Inc.
Medarex Announces Second Quarter Financial Results
PRINCETON, N.J

Aug. 10 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX - news) announced today second quarter results for the three-month period ending June 30, 2000. During this period, Medarex reported revenues and interest income totaling $9.7 million and a net loss of $5.6 million, or $0.16 per share. These results compare with revenues and interest income totaling $1.7 million and a net loss of $4.4 million, or $0.14 per share, for the same period in 1999. Included in the second quarter 2000 results, as a research and development expense, is the up-front payment of $5 million to Eos Biotechnology, Inc. pursuant to the strategic alliance entered into by the companies on Feb. 10, 2000. Medarex ended the second quarter with cash, cash equivalents and marketable securities of $372 million.

Significant Medarex events during the second quarter were


-- Launching an alliance with Biosite Diagnostics, Inc. aimed at
accelerating drug discovery using Trans-Phage Technology(SM), a high
throughput method of creating high-affinity, fully human antibodies;
-- Initiating a broad antibody development agreement with Johnson &
Johnson and its affiliates. Through this agreement, Johnson &
Johnson and its affiliates can access the HuMAb-Mouse® technology
for an unlimited number of targets;
-- Establishing a broad HuMAb-Mouse antibody development agreement with
MedImmune, Inc., including an exclusive, worldwide license for the
development of antibodies against respiratory syncytial virus (RSV);
-- Collaborating with Corixa Corporation to discover and develop high-
affinity fully human therapeutic antibodies;
-- Entering into a HuMAb-Mouse based collaboration with Coulter
Pharmaceuticals, Inc.; and
-- Appearing in various media outlets including CNNfn, Forbes Magazine
and CNBC.


``We have continued our momentum during the second quarter of the year by forming five new HuMAb partnerships, bringing our total number of HuMAb partners to 22,`` said Donald L. Drakeman, President and CEO of Medarex. ``We are very enthusiastic about the opportunities our new Trans-Phage Technology may provide for new partnerships, expansion of existing partnerships and for Medarex`s own internal product pipeline.``

Medarex also reported for the six-month period ended June 30, 2000 revenues and interest income totaling $13.8 million and a net loss of $9.9 million or $0.28 per share. These results compare with revenues and interest income totaling $7.6 million and a net loss of $5.4 million or $0.17 per share for the same period last year. The revenues and interest income increase for the six months ended June 30, 2000 relates principally to interest earned on the proceeds received from the March 3, 2000 follow-on public offering of Medarex`s Common Stock.

Medarex is a biopharmaceutical company developing monoclonal antibody- based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse® and TC Mouse(TM) systems for the creation of high-affinity, fully human antibodies; T-12 Development(SM) offering the capability of moving from target to trial in approximately 12 months; and Trans-Phage Technology(SM) combining high throughput screening with fully human antibody development. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about Medarex visit its web site at www.medarex.com.

Except for the historical information presented, certain matters discussed in this press release are forward-looking statements that are subject to unknown risks and uncertainties. These risks and uncertainties include, but are not limited to, the Company`s early stage of product development, history of operating losses and accumulated deficit, dependence on strategic alliances, government regulation of the biopharmaceutical industry and other risks that may be detailed from time to time in our periodic reports and registration statements filed with the Securities and Exchange Commission.

MEDAREX, INC.
Consolidated Statements of Operations
(unaudited)
(In thousands, except share data)

Three Months Ended Six Months Ended
June 30, June 30,
2000 1999 2000 1999

Sales $58 $443 $113 $487
Grants, contract
and license revenues 3,051 990 5,129 6,540
Total revenues 3,109 1,433 5,242 7,027
Costs and expenses:
Cost of sales 27 128 54 156
Research and
development 11,901 4,690 17,260 10,168
General and
administrative 3,018 1,334 5,905 2,616

Operating loss (11,837) (4,719) (17,977) (5,913)
Equity in net loss of
affiliate (158) 0 (158) 0
Interest and dividend
income 6,592 291 8,558 558
Interest expense (1) (2) (2) (4)
Loss before provision
for income taxes (5,404) (4,430) (9,579) (5,359)
Provision for income
taxes 150 0 300 0
Net loss $(5,554) $(4,430) $(9,879) $(5,359)
Basic and diluted net
loss per share $(.16) $(.14) $(.28) $(.17)
Weighted average shares
outstanding - basic
and diluted 35,763,557 31,663,866 34,829,279 31,585,959


Condensed Consolidated Balance Sheets
(In thousands)

June 30, December 31,
2000 1999
(unaudited)
Current assets, principally cash, cash
equivalents and marketable securities $383,024 $34,542
Property, plant and equipment, net 3,468 3,074
Investments in, and advances to affiliate 18,340 499
Other assets 22,189 2,367
$427,021 $40,482

Current liabilities $11,042 $12,160
Other liabilities 3,511 6,023
Shareholders` equity 412,468 22,299
$427,021 $40,482

SOURCE: Medarex, Inc.



hier der Link:
http://biz.yahoo.com/prnews/000810/nj_medarex.html

[MSolver]

PS:
da hat gegen 12:30 jemand seine 1000 St. Medx rausgeworfen!

[janolo]

verdammt, der Kurs haut nach unten ab. Sind die Zahlen denn wirklich so schlimm? Sollte man jetzt zügig rausgehen um dann wieder bei ca. 75 - 80 Euro einsteigen?
Wer hat Meinungen dazu.

SOS - Bitte melden

mfg janolo

[MSolver]

hi janolo,
ich sehe aktuell nur den Kurs in USA runter gehen(vorbörslich -4 %). Ich habe vorsichtshalber meine verkauft. Abwarten, der Kurs wird bei den Zahlen nicht nach oben abhauen, bestimmt!

MSolver

[MSolver]

und noch etwas:
der Kursverlauf der letzten Tage hat dieses schon angedeutet bzw. sehen wir bei den Zahlen die Erklärung. Jedes mal als der Kurs in den vergangenen Tage etwas stärker angezogen hat haute einer von oben mit dem Hammer drauf! (Verkauf !)

[ballard1]

scheint so, als wäre ich wieder dabei, trotzdem sehe ich den Kursverlauf von Medarex relativ stabil. Was interessieren bei so einem Wert die Zahlen.
Haben wohl mehrere Phase III Projekte, derne Phantasie vom Markt honoriert wird.
Hätte trotzdem gern nochmals Kurse um die $50-60

[johnnywinter]

@Msolver

Hallo

Könntest Du mir bitte sagen, wie ich an die vorbörslichen Zahlen in den USA herankomme?

Ich danke Dir+

Gruß

Johnny Winter

[Skorpy]

MSolver Hy du ... sag mal wo kann man denn nachsehen wo man sieht das
jemand so viele aktien (1000) abgestossen hat?
Bitte um Antwort danke im voraus
Skorpy,,

[MSolver]

@johnnywinter

www.Datek.com

@Skorpy
entweder schaut man in das Orderbuch(doch das kosten richtig Geld) oder aber folgende vereinfachte, aber meist zutreffende, Situation:

Der Kurs fällt mit großen Stückzahlen:
Da hat jemand z.B. bestens verkauft, und es werden an alle die Aktien verkauft die im Bid eine Order stehen haben. Folglich -> Kurs fällt und der Kurs im Bid fällt auch !


Der Kurs steigt mit großen Stückzahlen:
Es kauft jemand z.B. bestens. Es werden alle Aktien gekauft die im Ask stehen. Der Kurs steigt und das mit einer Order, zusätzlich steigt der Kurs im Ask!

Alles etwas vereinfacht dargestellt !!


MSolver

[MSolver]

@ballard1
der Kurs relativ stabil ?,
denke ich derzeit mit - 18 % nicht !!!!

[ballard1]

@msolver, mein Posting bezog sich auf den Kursverlaub bis einschl. 09.08.
Cool bleiben, Medarex fallen, weil Sie wieder zu mir zurück wollen

[MSolver]

zugegeben, den Rebound habe ich auch nicht erwartet !